Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 22 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-11.23 Insider Own0.01% Shs Outstand80.82M Perf Week-18.03%
Market Cap25.57M Forward P/E- EPS next Y-3.16 Insider Trans0.00% Shs Float80.81M Perf Month8.39%
Income-123.42M PEG- EPS next Q-1.46 Inst Own20.85% Short Float0.79% Perf Quarter-34.22%
Sales3.99M P/S6.41 EPS this Y59.05% Inst Trans25.59% Short Ratio0.36 Perf Half Y-66.24%
Book/sh6.80 P/B0.05 EPS next Y62.29% ROA-63.37% Short Interest0.64M Perf Year-94.02%
Cash/sh0.09 P/C3.70 EPS next 5Y- ROE-69.20% 52W Range0.26 - 5.37 Perf YTD-21.49%
Dividend Est.- P/FCF- EPS past 5Y79.97% ROI-101.54% 52W High-94.11% Beta2.26
Dividend TTM- Quick Ratio1.02 Sales past 5Y0.00% Gross Margin-49.94% 52W Low21.69% ATR (14)0.03
Dividend Ex-Date- Current Ratio1.77 EPS Y/Y TTM68.08% Oper. Margin-3103.01% RSI (14)42.21 Volatility8.57% 8.33%
Employees117 Debt/Eq0.01 Sales Y/Y TTM- Profit Margin-3094.01% Recom1.00 Target Price5.83
Option/ShortNo / Yes LT Debt/Eq0.01 EPS Q/Q57.74% Payout- Rel Volume0.70 Prev Close0.35
Sales Surprise-31.22% EPS Surprise-22.82% Sales Q/Q- EarningsNov 09 AMC Avg Volume1.77M Price0.32
SMA20-6.47% SMA50-13.95% SMA200-66.30% Trades Volume1,232,200 Change-9.57%
Date Action Analyst Rating Change Price Target Change
Apr-18-22Initiated Noble Capital Markets Outperform
Apr-18-19Upgrade ROTH Capital Neutral → Buy $4
Aug-18-17Upgrade ROTH Capital Neutral → Buy $6
Sep-07-16Downgrade ROTH Capital Buy → Neutral
Feb-17-16Reiterated Oppenheimer Outperform $18 → $10
Nov-04-15Initiated Cantor Fitzgerald Buy
Jun-12-15Initiated Oppenheimer Outperform $18
Feb-17-15Reiterated ROTH Capital Buy $10 → $12
Sep-29-14Reiterated ROTH Capital Buy $17 → $10
Feb-20-24 08:00AM
Feb-16-24 09:30AM
Feb-15-24 08:45AM
Feb-14-24 08:00AM
08:00AM Loading…
Feb-13-24 08:00AM
Feb-12-24 08:00AM
Feb-01-24 08:00AM
Jan-31-24 07:00AM
Jan-30-24 05:00PM
Jan-29-24 07:00AM
Jan-26-24 05:31PM
Jan-25-24 07:00AM
Jan-24-24 03:28PM
Jan-09-24 07:00AM
07:00AM Loading…
Jan-03-24 07:00AM
Jan-02-24 06:08AM
Dec-20-23 10:35AM
Dec-14-23 09:15AM
Dec-12-23 01:40PM
Dec-11-23 07:00AM
Dec-04-23 07:00AM
Nov-28-23 07:00AM
Nov-20-23 01:57PM
Nov-15-23 07:00AM
Nov-13-23 07:00AM
Nov-09-23 04:15PM
Nov-02-23 08:00AM
05:00PM Loading…
Oct-31-23 05:00PM
Oct-30-23 07:00AM
Oct-26-23 07:00AM
Oct-25-23 08:45AM
Oct-19-23 07:00AM
Oct-18-23 07:00AM
Oct-16-23 07:00AM
Oct-12-23 07:00AM
Oct-11-23 07:00AM
Oct-09-23 07:00AM
Oct-04-23 07:00AM
Sep-28-23 09:00PM
Sep-27-23 08:30AM
Sep-26-23 10:18AM
Sep-21-23 07:00AM
Sep-19-23 01:54PM
Sep-18-23 07:00AM
Sep-15-23 09:30AM
Sep-14-23 07:00AM
Sep-06-23 07:00AM
Sep-05-23 07:32AM
Aug-28-23 01:13PM
Aug-21-23 01:18PM
Aug-17-23 07:00AM
Aug-16-23 07:00AM
Aug-10-23 04:30PM
Aug-07-23 07:00AM
Aug-01-23 04:01PM
Jul-31-23 07:00AM
Jul-27-23 09:31PM
Jul-26-23 04:05PM
Jul-24-23 07:00AM
Jul-17-23 07:00AM
Jul-10-23 07:00AM
Jul-06-23 08:09AM
Jul-03-23 07:00AM
Jun-28-23 03:21PM
Jun-26-23 07:00AM
Jun-21-23 08:25AM
Jun-15-23 07:00AM
Jun-07-23 07:00AM
Jun-05-23 07:00AM
May-31-23 01:24PM
May-30-23 07:00AM
May-25-23 04:05PM
May-24-23 07:00AM
May-23-23 07:00AM
May-22-23 07:00AM
May-18-23 07:00AM
May-17-23 07:00AM
May-09-23 01:00PM
May-08-23 07:00AM
May-04-23 07:00AM
May-01-23 11:35AM
Apr-27-23 08:00AM
Apr-24-23 11:34AM
Apr-19-23 07:00AM
Apr-17-23 07:00AM
Apr-13-23 02:12PM
Apr-06-23 04:15PM
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.